|
|
2024-04-15 00:00:00
|
Novartis and Sandoz Lead Foreign Investment in Slovenia's Thriving Pharma Sector
Slovenia's pharmaceutical industry continues to attract significant foreign direct investment, standing out as the country's most appealing sector for international capital. Sandoz, a division of Novartis, has announced a commitment to invest 400 million euros over the next three years in a cutting-edge facility for biosimilar drug production in Lendava. Meanwhile, Novartis has already injected 245 million euros into enhancing its production capabilities in Ljubljana and expanding the Biocampus in Mengeš, making Slovenia the pivotal global manufacturing hub for the corporation's biologic drug ingredients.
The investment landscape in Slovenia was further enriched in 2023 by substantial contributions from other sectors. German luxury motorhome manufacturer Carthago allocated 50 million euros to a new production site in Ormož, situated in northeastern Slovenia. Similarly, Goodyear, a leader in the global tire and rubber industry, finalized a 94 million euro investment to broaden its manufacturing operations in Kranj.
Looking ahead, BSH, a renowned producer of home appliances, is gearing up to establish a new factory in Nazarje with an investment of 80 million euros. Additionally, two German enterprises—EBM Papst, a producer of small electric motors, and Herz, a specialist in heating, cooling, and sanitary systems—are poised to commence construction on new manufacturing plants in Slovenia.
The country's dynamic investment environment is also highlighted by recent acquisitions. The Volution Group from Britain has acquired a significant interest in iVent, a Slovenian innovator in ventilation systems recognized for its rapid growth. Furthermore, FTA Šentjur, a producer of electronic components, has joined the German TQ Group as of March 2024, showcasing the continued confidence of foreign investors in Slovenia's diverse industrial sectors.
|
|
|